Anti-Obesity Treatments Report -

Analysis & Forecasts 2009-2024

Download reportDownload sample

• Publication date: 23/02/2009

• Number of Pages: 175

1. Report Details
2. Table of Contents
3. Companies Listed

Report Details

Obesity has been described as a 'public health time-bomb'. In 2005, the World Health
Organization estimated that approximately 400 million individuals are obese. Prevalence
of obesity is rising worryingly in many countries, despite campaigns emphasising the link
between being overweight and contracting diabetes. This new report - Anti-Obesity
Treatments 2009-2024 – explains those trends in commercial terms. In two of the largest
national markets for anti-obesity treatments - the US and UK - over 20% of the
population are seriously overweight. Obesity is a major risk factor in a number of other
serious disorders, particularly diabetes and heart disease. Importantly, the financial
burden of obesity and its associated conditions - both direct and indirect costs - are vast.
Obesity is a serious, chronic condition with an emerging market for therapeutic products,
as we show in this study. High socioeconomic costs and increasing prevalence are
inspiring government initiatives to deal with the problem, with obesity becoming one of
the most prominent global health concerns worldwide. Visiongain recognizes the
contribution of drugs in this important emerging market, as diet and exercise are
frequently not successful alone. We predict that new classes of drugs will invigorate the
market - driving total sales in the next decade. In this report you will find out about those
treatments, especially their sales potential.

Drug sales in the global anti-obesity market approached $2bn in 2008, with the market to grow
substantially over the forecast period 2009-2024. This growth will be associated with a complex
environment of label changes, reformulations, patent expiry, OTC switching and new product
launches. Those opportunities are highlighted by the extensive R&D pipeline, crowded with
novel therapies to improve treatment of obesity. Which new treatments have blockbuster
potential? Our report will cover this and other important matters. Importantly, too, prevalence of
obesity is rising in Latin America, India and China in particular – important pharmaceutical
markets covered here.

Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global anti-obesity

market, with comprehensive sales forecasting. With a rigorous study of sources, including
commercial databases, company reports, industry news and first-hand interviews with
experts in the obesity sector, this report is a unique opportunity to discover how your
company can develop over the next 5 years. The result is a comprehensive market- and
industry-based report with detailed analyses and informed opinion that you will not find
anywhere else.

Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the

market:
• A global forecast for the anti-obesity drugs market with comprehensive discussions
• Sales forecasts for the current-leading drugs
• Assessment of new drug releases, both therapeutically and commercially
• Sales forecasts for the leading national anti-obesity markets, as well as for emerging
national markets
• Discussion of strengths, weakness, opportunities and threats (SWOT) facing major
stakeholders in the anti-obesity drug sector
• Extensive analysis of pipeline developments, including avenues for future research
• Discussion of current un-met and under-met needs in the anti-obesity market, revealing
both therapeutic needs and commercial opportunities.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for anti-obesity therapies from
2009-2024, including predicted revenues, growth rates and other key metrics
• To identify key pipeline developments, the most promising therapy classes and potential
methods of treatment
• To discover the important drivers and restraints for the global anti-obesity market,
including factors affecting leading national markets
• To find out where the global anti-obesity market is heading - both technologically and
commercially - from the present onwards.

This report is essential reading for anyone in the pharmaceutical and healthcare sector
with an interest in obesity and related conditions. Purchasing this report will help you to
recognise those important market opportunities and understand the possibilities there.

Visiongain ltd.

4th Floor,

BSG House,
226 236 City Road,

London

EC1V 2QY

United Kingdom

Telephone: +44 (0) 20 7336 6100

Fax: +44 (0) 20 7549 9930

info@visiongainglobal.com

Or Visit at: http://www.visiongain.com/Report.aspx?rid=367

Or http://www.visiongain.com

Or

Contact Person

Suvitha Damodaran

suvitha.damodaran@visiongainglobal.com

Direct Line: +44 (0)20 7549 9946

+44 (0)20 7336 6100